Literature DB >> 1998305

Use of intravenous albumin in the critically ill patient.

R D Guthrie1, C Hines.   

Abstract

The experimental data supporting and opposing the use of intravenous albumin in various groups of patients are provided, and conclusions are drawn from these data. The metabolism and kinetics of albumin are reviewed, and the importance of albumin levels in critically ill patients is discussed. The reviewed literature supports the conclusion that in most critically ill patients, intravenous albumin does not improve outcome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998305

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 3.  [Guidelines on therapy with blood components and plasma derivatives: human albumin. Recommendations of the scientific advisory board of the Medical Council].

Authors:  J Boldt
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

4.  Volume replacement strategies on intensive care units: results from a postal survey.

Authors:  J Boldt; M Lenz; B Kumle; M Papsdorf
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

5.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.

Authors:  Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

6.  Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial.

Authors:  Thiemo F Veneman; Jeroen Oude Nijhuis; Arend J J Woittiez
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

7.  Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.

Authors:  Samantha N Reiss; Larry W Buie; Nelly Adel; Debra A Goldman; Sean M Devlin; Dan Douer
Journal:  Ann Hematol       Date:  2016-08-20       Impact factor: 3.673

8.  Albumin bolus administration versus continuous infusion in critically ill hypoalbuminemic pediatric patients.

Authors:  A Greissman; P Silver; L Nimkoff; M Sagy
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.